Canouï Etienne, Lécuroux Camille, Avettand-Fenoël Véronique, Gousset Marine, Rouzioux Christine, Saez-Cirion Asier, Meyer Laurence, Boufassa Faroudy, Lambotte Olivier, Noël Nicolas
Assistance Publique-Hôpitaux de Paris (AP-HP), Service de Médecine Interne et Immunologie Clinique, Groupe Hospitalier Universitaire Paris Sud, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche 1184, Immunologie des Maladies Virales et Autoimmunes, Université Paris Sud, Le Kremlin-Bicêtre, France.
Open Forum Infect Dis. 2017 Apr 3;4(2):ofx064. doi: 10.1093/ofid/ofx064. eCollection 2017 Spring.
Human immunodeficiency virus controllers (HICs) form a heterogeneous group of patients with regard to formal definitions, immunologic characteristics, and changes over time in viral load.
The HICs with undetectable viral load ([uHICs] ie, for whom a viral load had never been detected with routine assays; n = 52) were compared with 178 HICs with blips during the follow up (bHICs). Clinical characteristics, ultrasensitive HIV-ribonucleic acid (RNA) and HIV-deoxyribonucleic acid (DNA) loads, HIV1-Western blot profiles, and immune parameters were analyzed.
Relative to bHICs, uHICs had significantly lower ultrasensitive plasma HIV-RNA loads ( < .0001) and HIV-DNA levels in peripheral blood mononuclear cells ( = .0004), higher CD4 T-cell count ( = .04) at enrollment, and lower T-cell activation levels. Between diagnosis and inclusion in the cohort, the CD4 T-cell count had not changed in uHICs but had significantly decreased in bHICs. Twenty-one percent of the uHICs lacked specific anti-HIV immunoglobulin G antibodies, and these individuals also had very low levels of HIV-DNA. Half of the uHICs had a protective human leukocyte antigen (HLA) allele (-B57/58/B27), a weak CD8 T-cell response, and very small HIV-DNA reservoir.
We suggest that an interesting HIC phenotype combines protective HLA alleles, low level of HIV blood reservoirs, and reduced immune activation. Prospective studies aimed at evaluating the benefit of combined antiretroviral therapy in HICs might take into account the identification of uHICs and bHICs.
就正式定义、免疫特征以及病毒载量随时间的变化而言,人类免疫缺陷病毒控制者(HICs)构成了一组异质性患者群体。
将病毒载量不可检测的HICs([uHICs],即通过常规检测从未检测到病毒载量的患者;n = 52)与随访期间出现病毒载量波动的178例HICs(bHICs)进行比较。分析了临床特征、超敏HIV核糖核酸(RNA)和HIV脱氧核糖核酸(DNA)载量、HIV-1蛋白印迹图谱以及免疫参数。
相对于bHICs,uHICs的超敏血浆HIV-RNA载量显著更低(P <.0001),外周血单个核细胞中的HIV-DNA水平更低(P =.0004),入组时CD4 T细胞计数更高(P =.04),且T细胞活化水平更低。在诊断至纳入队列期间,uHICs的CD4 T细胞计数未发生变化,而bHICs的CD4 T细胞计数显著下降。21%的uHICs缺乏特异性抗HIV免疫球蛋白G抗体,这些个体的HIV-DNA水平也非常低。一半的uHICs具有保护性人类白细胞抗原(HLA)等位基因(-B57/58/B27)、较弱的CD8 T细胞反应以及非常小的HIV-DNA储存库。
我们认为一种有趣的HIC表型包括保护性HLA等位基因、低水平的HIV血液储存库以及免疫激活降低。旨在评估联合抗逆转录病毒疗法对HICs益处的前瞻性研究可能需要考虑uHICs和bHICs的识别。